share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

香港交易所 ·  Feb 6 07:24
Summary by Moomoo AI
藥明生物（药明生物技术有限公司）於2024年2月6日完成了一系列股份購回交易，並於翌日向香港聯合交易所有限公司披露。根據披露報表，該公司在2023年12月7日至2024年2月6日期間，進行了多次股份購回，但並未註銷這些股份。最後一次購回發生在2024年2月6日，當日購回股份數目為11,916,000股，每股價格介於HKD 17.06至HKD 18.28之間，總付出金額為HKD 213,442,510。自普通決議案通過以來，公司在香港聯交所購回的股份總數達到70,269,500股，佔已發行股份的1.65402%。藥明生物確認，所有購回行為均符合主板上市規則及GEM上市規則的相關規定。
藥明生物（药明生物技术有限公司）於2024年2月6日完成了一系列股份購回交易，並於翌日向香港聯合交易所有限公司披露。根據披露報表，該公司在2023年12月7日至2024年2月6日期間，進行了多次股份購回，但並未註銷這些股份。最後一次購回發生在2024年2月6日，當日購回股份數目為11,916,000股，每股價格介於HKD 17.06至HKD 18.28之間，總付出金額為HKD 213,442,510。自普通決議案通過以來，公司在香港聯交所購回的股份總數達到70,269,500股，佔已發行股份的1.65402%。藥明生物確認，所有購回行為均符合主板上市規則及GEM上市規則的相關規定。
Pharmaceutical Biotech (Pharmaceutical Biotechnology Co., Ltd.) completed a series of share repurchase transactions on 6 February 2024 and disclosed it to the Hong Kong Stock Exchange Limited the following day. According to the disclosure, the company made several share repurchases between December 7, 2023 and February 6, 2024, but did not write them off. The last repurchase took place on 6 February 2024. The number of shares repurchased on that date was 11,916,000 shares, priced between HKD 17.06 and HKD 18.28 for a total payment of HKD 213,442,510. Since the adoption of the Ordinary Resolution, the total number of shares repurchased on the Hong Kong Stock Exchange has reached 70,269,500 shares, representing 1.65402% of the issued shares. Pharmacobiology confirms that all repurchases comply with the relevant provisions of the Main Board Listing Rules and the GEM Listing Rules.
Pharmaceutical Biotech (Pharmaceutical Biotechnology Co., Ltd.) completed a series of share repurchase transactions on 6 February 2024 and disclosed it to the Hong Kong Stock Exchange Limited the following day. According to the disclosure, the company made several share repurchases between December 7, 2023 and February 6, 2024, but did not write them off. The last repurchase took place on 6 February 2024. The number of shares repurchased on that date was 11,916,000 shares, priced between HKD 17.06 and HKD 18.28 for a total payment of HKD 213,442,510. Since the adoption of the Ordinary Resolution, the total number of shares repurchased on the Hong Kong Stock Exchange has reached 70,269,500 shares, representing 1.65402% of the issued shares. Pharmacobiology confirms that all repurchases comply with the relevant provisions of the Main Board Listing Rules and the GEM Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more